Press

Salamanca to host the Green Innovation Forum 2026

13/01/2026

Climate change · Agrifood · Food & feed · Agriculture · Bioeconomy · Circular economy

• The sixth edition, organized by AseBio and the Salamanca City Council, will take place on April 21 at the Castilla y León Conference and Exhibition Centre.
• The forum has positioned itself as a unique meeting point for leading Spanish and international companies and research institutions specializing in green biotechnology.
• Salamanca is consolidating its position as a technology hub thanks to the joint efforts of the City Council, universities, research centers, and companies under the Salamanca Tech initiative.

AseBio

Cristina Nadal, Executive Director of Government Affairs at MSD Spain, appointed new President of the Spanish Bioindustry Association

18/12/2025

Corporate

• At AseBio’s General Assembly, the new Vice Presidents were also elected: Rocío Arroyo (Amadix), Santiago de Torres (Atrys), and Carlota Gómez de la Hoz (Hipra).
• The AseBio General Assembly also elected eight members of its Board of Directors.
• “It is time to promote a biotechnology that is present in public and strategic conversations,” said Cristina Nadal.

AseBio

AseBio positively assesses the foundations of the Biotech Act proposal

17/12/2025

Healthcare

• Following its recent launch, it aims to boost Europe’s biotechnological potential and accelerate the transition from research to market, while strengthening the EU’s industrial capacity and strategic autonomy in health.
• Throughout the entire process of drafting the proposal, AseBio has actively participated in its design together with our members and in close collaboration with EuropaBio.
• At the national level, it represents a unique opportunity to drive the growth of the Spanish biotechnology sector. Therefore, in Spain it should be a priority to build on the foundations laid by the Biotech Act in order to fully develop the potential of our sector.

AseBio

AseBio and FATE sign an agreement to boost innovation in biotechnology, foodtech and agritech at national and European level

11/12/2025

Agrifood · Food & feed · Agriculture

• The agreement responds to the complementarity of objectives and lines of work between both organizations and reinforces AseBio’s commitment to sustainable agriculture and food innovation.
• AseBio and FATE–Food&AgriTech Europe aim to consolidate a cooperation framework that promotes innovation, facilitates knowledge exchange and strengthens European leadership in the Foodtech and Agritech sectors.

AseBio

The European sector urges the EU to avoid new restrictions and to conclude a coherent, science-based agreement on NGTs

03/12/2025

Climate change · Agrifood · Food & feed · Agriculture · Gene editing

• The third and final round of trilogues begins to finalize an agreement on the Regulation on plants obtained through New Genomic Techniques (NGTs) and the food and feed derived from them.
• After months of negotiations, 25 European organizations have sent a letter to Parliament calling for the avoidance of unjustified new restrictions and for support of a final agreement consistent with the original proposal.
• At AseBio, we fully endorse this joint letter, as the future of European agriculture and its competitiveness depends on having a proportionate, clear regulatory framework aligned with scientific evidence.
   

AseBio

Adigital, AESEMI and AseBio drive a joint proposal to position Spain at the forefront of deep technologies

25/11/2025

Healthcare · Access to innovation · Financing

• The three national associations have submitted a joint document to the Ministry of Science, Innovation and Universities containing 13 concrete proposals to respond to the public consultation and guide the future Spanish Deep Technologies Strategy.
• The aim of this document is to promote a specific regulatory framework that recognises these technologies as a strategic sector for the country’s technological autonomy and competitiveness, as well as measures to ensure the creation of coordinated ecosystems, integrated value chains, and economic instruments that complement scientific research and development.

AseBio

Biotechnology, key to curbing antimicrobial resistance and strengthening European health security

21/11/2025

Healthcare · Antibiotic resistance · Animal health

• In 2021, antimicrobial resistance was involved in at least 4.7 million deaths worldwide, including 35,000 annual deaths in Europe and around 4,000 in Spain.
• The WHO warns of a sustained increase in resistant infections—one in six in 2023—especially caused by multidrug-resistant bacteria such as Escherichia coli and Klebsiella pneumoniae.
• Biotechnology is emerging as a strategic ally to develop new antibiotics, therapies, vaccines, and rapid diagnostic tools, as well as to apply artificial intelligence and large-scale data analysis in epidemiological surveillance.

AseBio

A 20% increase in survival through early diagnosis: biotechnology accelerates change in the fight against the deadliest tumour

17/11/2025

Healthcare

• Low-dose CT screening can significantly reduce mortality and increase patient survival by around 20%, according to international scientific evidence
• Biotechnology is revolutionising lung cancer diagnosis and treatment through technologies such as next-generation sequencing, liquid biopsy, spatial transcriptomics and single-cell analysis.
• Spain continues to make progress in translational research thanks to groups like CIBERONC, although major challenges remain, including therapeutic resistance, tumour heterogeneity and the absence of a population-wide screening programme.

AseBio

Innovation, research, and the future: biotechnology sets the course for psoriasis treatment

29/10/2025

Healthcare · Access to innovation · Innovative drugs

• Biotechnology enables the development of more effective and personalized treatments for chronic inflammatory diseases such as psoriasis, improving the quality of life for millions of people.
• Inhibitec Anticuerpos, an AseBio member company, is researching a new therapeutic target called BAMBI, with promising results in both the skin and joint manifestations of the disease.
• Collaboration with patients and international foundations drives research that is closer, more human, and focused on the real needs of those living with psoriasis.

AseBio